ALPS Advisors’s Fortress Biotech FBIO Stock Holding History

ALPS Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,827	Closed	-$139K	–	1056
2022 Q1	$139K	Sell	6,827 -859	-11%	-$23.5K	﹤0.01%	820
2021 Q4	$288K	Sell	7,686 -501	-6%	-$22.3K	﹤0.01%	841
2021 Q3	$395K	Sell	8,187 -358	-4%	-$17.5K	﹤0.01%	567
2021 Q2	$458K	Sell	8,545 -2,757	-24%	-$166K	﹤0.01%	531
2021 Q1	$598K	Buy	11,302 +797	+8%	+$45K	0.01%	478
2020 Q4	$499K	Buy	+10,505	New	+$455K	0.01%	499

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

ALPS Advisors's FBIO Position: Q2 2022 in Review

ALPS Advisors sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 6,827 shares — an estimated $139K sold.

ALPS Advisors first reported a position in FBIO in Q4 2020 and held it in 6 quarters. The position peaked at $598K in Q1 2021. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

ALPS Advisors reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
ALPS Advisors sold 6,827 Fortress Biotech shares in Q2 2022, an estimated $139K.
ALPS Advisors first reported a position in Fortress Biotech in Q4 2020 and held it in 6 quarters.
ALPS Advisors's Fortress Biotech position peaked at $598K in Q1 2021.
66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.